Nektar Branches Out In Pain, Hails Next Generation Of Analgesics
Executive Summary
At R&D event, company signals shift of Phase III for lead pain drug NKTR-181 to mid-2014 from earlier in the year. Nektar also featured crop of new drugs targeted at different molecular pathways, including NKTR-192, a partial agonist for acute pain, and a new kind of sodium channel blocker called NKTR-171 for neuropathy.
You may also be interested in...
Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug
Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.
Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer
Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.
Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer
Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.